Literature DB >> 12092656

Radical cystectomy versus alternative treatments for muscle-confined bladder cancer.

A Tekin1, F T Aki, H Ozen.   

Abstract

Of the 100 patients with muscle-confined transitional cell cancer of the bladder and ASA score < or = 3, 59 underwent radical cystectomy (RC) and 41 received non-cystectomy alternative treatments (AT). Median follow-up was 30.8 and 30.5 months in RC and in AT groups, respectively. Disease-free and overall survivals were significantly longer in RC group than AT group. Salvage cystectomy was required in approximately 25% of the patients who received AT. AT was associated with higher rate of cancer-related morbidity and cancer progression than RC. Every patient with invasive bladder cancer should be given a chance for cystectomy.

Entities:  

Mesh:

Year:  2001        PMID: 12092656     DOI: 10.1023/a:1015261628978

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  21 in total

Review 1.  Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder.

Authors:  M A Dimopoulos; L A Moulopoulos
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

2.  Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy?

Authors:  R E Hautmann; T Paiss
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

3.  Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire.

Authors:  O Caffo; G Fellin; U Graffer; L Luciani
Journal:  Cancer       Date:  1996-09-01       Impact factor: 6.860

Review 4.  The role of radiation therapy in the management of transitional cell carcinoma of the bladder.

Authors:  M K Gospodarowicz; P Warde
Journal:  Hematol Oncol Clin North Am       Date:  1992-02       Impact factor: 3.722

5.  Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

Authors:  W G Harker; F J Meyers; F S Freiha; J M Palmer; L D Shortliffe; J F Hannigan; K M McWhirter; F M Torti
Journal:  J Clin Oncol       Date:  1985-11       Impact factor: 44.544

6.  Bladder carcinoma as a systemic disease.

Authors:  G R Prout; P P Griffin; W U Shipley
Journal:  Cancer       Date:  1979-06       Impact factor: 6.860

7.  Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. A retrospective analysis of 317 patients.

Authors:  S D Fosså; H Waehre; N Aass; A B Jacobsen; D R Olsen; S Ous
Journal:  Cancer       Date:  1993-11-15       Impact factor: 6.860

8.  Five-year results of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy plus radical cystectomy in locally advanced bladder cancer.

Authors:  V Scattoni; L Da Pozzo; L Nava; L Broglia; L Galli; T Torelli; B Campo; M Maffezzini; P Rigatti
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

9.  Radical cystectomy without radiation therapy for carcinoma of the bladder.

Authors:  J E Montie; R A Straffon; B H Stewart
Journal:  J Urol       Date:  1984-03       Impact factor: 7.450

10.  Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.

Authors:  J C Angulo; M Sanchez-Chapado; J I Lopez; N Flores
Journal:  J Urol       Date:  1996-06       Impact factor: 7.450

View more
  2 in total

1.  The rationale for radical cystectomy as primary therapy for T4 bladder cancer.

Authors:  Udo Nagele; Aristotelis G Anastasiadis; Axel S Merseburger; Stefan Corvin; Jörg Hennenlotter; Melanie Adam; Karl-Dietrich Sievert; Arnulf Stenzl; Markus A Kuczyk
Journal:  World J Urol       Date:  2007-05-25       Impact factor: 4.226

2.  Surgical approach in patients with T4 bladder cancer as primary treatment: Disaster or option with improved quality of life.

Authors:  Udo Nagele; Aristotelis G Anastasiadis; Axel S Merseburger; Jörg Hennenlotter; Markus Horstmann; Karl-Dietrich Sievert; Arnulf Stenzl; Markus A Kuczyk
Journal:  Indian J Urol       Date:  2008-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.